Skip to main content
S&P 5007,591.08-0.59%DOW52,000.36-0.73%NASDAQ26,092.15-0.61%BTC$77,086.00-1.88%ETH$2,459.99-1.15%GOLD$4,379.60-1.82%OIL$102.30+6.51%
Smart Investors Daily
CA

NASDAQ · CAI

Caris Life Sciences, Inc.

Healthcare · Biotechnology

$24.03

Down-$0.21 (-0.87%)

Updated Sep 10, 2026, 6:44 PM

SID Score

6.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
7.49B
P/E ratio
-34.61
Dividend yield
0.00%
52-week range
$14.19 – $29.32
Volume
3.15M
Avg. volume
1.42M

Price performance

CAI price history

1M range · 20 trading sessions · Daily adjusted prices

CAI closed at $24.03 after 20 trading sessions, up 7.95% for the selected period.

Last close
$24.03
Period change
+7.95%
Period low
$20.97
Period high
$28.01
Daily close
View OHLC price history
CAI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$24.00$24.96$23.95$24.033.15M
Sep 8, 2026$25.03$25.68$24.74$24.824.58M
Sep 4, 2026$24.88$25.14$24.4718$25.074.71M
Sep 3, 2026$24.94$25.34$23.62$25.326.43M
Sep 2, 2026$25.13$25.615$24.505$24.805.49M
Sep 1, 2026$25.60$25.62$24.55$24.784.03M
Aug 31, 2026$25.35$25.56$24.48$25.495.87M
Aug 28, 2026$26.15$26.75$25.47$25.633.84M
Aug 27, 2026$26.82$27.385$26.36$26.3810.9M
Aug 26, 2026$27.70$28.0895$26.26$26.824.03M
Aug 25, 2026$26.19$28.32$25.77$28.016.82M
Aug 24, 2026$25.84$26.66$25.40$26.135.8M
Aug 21, 2026$24.73$26.60$24.32$26.276.39M
Aug 20, 2026$22.59$24.765$22.59$24.586.03M
Aug 19, 2026$21.92$22.94$21.92$22.766.56M
Aug 18, 2026$21.31$21.64$20.78$20.973.6M
Aug 17, 2026$22.00$22.19$21.52$21.632.77M
Aug 14, 2026$22.26$22.43$21.445$21.803.87M
Aug 13, 2026$22.84$23.12$22.14$22.182.97M
Aug 12, 2026$22.90$22.965$21.99$22.264.02M

Latest CAI news

The latest Smart Investors Daily articles mentioning CAI.

Stock researchCompany · Overview

CAI research

Overview

Company profile and research snapshot.

Company profile

Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$35.00
Implied upside
—
Analysts
12
CAI recent ratings
DateFirmRatingTarget
Sep 9, 2026UBSNeutral—
Aug 6, 2026Evercore ISI GroupOutperform—
Aug 6, 2026BTIGBuy—
Jul 6, 2026Evercore ISI GroupOutperform—
Jul 2, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 5, 2026

Caris Life Sciences (CAI) Will Present Seven Studies At A Global Lung Conference

Caris Life Sciences (NasdaqGS: CAI) announced plans to present seven major precision oncology studies at the IASLC 2026 World Conference on Lung Cancer. The company highlighted new data on molecular profiling and AI powered analysis for lung cancer care. Caris also published a validated AI driven method designed to help optimize first line pancreatic cancer treatment choices. For readers following how AI is reshaping cancer research and treatment, it can also be useful to look at other...

Yahoo · Sep 2, 2026

Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer

Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present seven studies at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), taking place September 12-15, 2026, in Seoul, South Korea. Caris research includes two mini oral presentations, one Poster Tour presentation and four poster presentations highlighting how comprehe

Yahoo · Aug 27, 2026

Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By